A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
A phase 1/2 trial of MBS314 Injection in multiple myeloma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
Overview
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. is a phase 1/2 interventional study registered as NCT06232096 by Beijing Mabworks Biotech Co., Ltd., with 154 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-02. Interventions recorded: MBS314 Injection.
Similar pages
not linked directly; found by shared links- TrialA Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Shares Beijing Mabworks Biotech and the tag pipeline.
- TrialMIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Shares Beijing Mabworks Biotech and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.